Robeco Schweiz AG Trims Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Robeco Schweiz AG lessened its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 17.5% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 136,557 shares of the medical research company's stock after selling 28,987 shares during the period. Thermo Fisher Scientific accounts for approximately 1.7% of Robeco Schweiz AG's holdings, making the stock its 20th biggest position. Robeco Schweiz AG's holdings in Thermo Fisher Scientific were worth $67,951,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in TMO. Revolve Wealth Partners LLC increased its holdings in Thermo Fisher Scientific by 4.2% in the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock valued at $255,000 after buying an additional 20 shares during the last quarter. One Charles Private Wealth Services LLC boosted its position in shares of Thermo Fisher Scientific by 4.2% during the 4th quarter. One Charles Private Wealth Services LLC now owns 499 shares of the medical research company's stock worth $260,000 after acquiring an additional 20 shares in the last quarter. Holderness Investments Co. raised its position in shares of Thermo Fisher Scientific by 1.7% during the 4th quarter. Holderness Investments Co. now owns 1,277 shares of the medical research company's stock worth $664,000 after acquiring an additional 21 shares in the last quarter. Port Capital LLC lifted its stake in Thermo Fisher Scientific by 1.6% during the fourth quarter. Port Capital LLC now owns 1,385 shares of the medical research company's stock worth $721,000 after purchasing an additional 22 shares during the last quarter. Finally, Clark Capital Management Group Inc. boosted its holdings in Thermo Fisher Scientific by 0.5% in the fourth quarter. Clark Capital Management Group Inc. now owns 4,445 shares of the medical research company's stock valued at $2,312,000 after purchasing an additional 23 shares in the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on TMO. Wells Fargo & Company reduced their price objective on shares of Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating for the company in a research report on Thursday, April 24th. Robert W. Baird decreased their price objective on shares of Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating for the company in a research note on Thursday, April 24th. Royal Bank Of Canada cut their target price on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating on the stock in a research report on Thursday, April 24th. Stifel Nicolaus decreased their target price on Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating for the company in a research report on Thursday, April 24th. Finally, Scotiabank raised Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price target on the stock in a research report on Friday. Four analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $600.30.

Thermo Fisher Scientific Stock Performance

Shares of Thermo Fisher Scientific stock traded up $4.29 on Friday, reaching $435.02. 2,511,384 shares of the stock were exchanged, compared to its average volume of 1,999,630. The company has a current ratio of 1.77, a quick ratio of 1.38 and a debt-to-equity ratio of 0.64. The firm has a market capitalization of $164.22 billion, a PE ratio of 25.51, a PEG ratio of 2.31 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $627.88. The business has a fifty day moving average price of $409.39 and a two-hundred day moving average price of $476.23.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The business had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.23 billion. During the same period in the prior year, the business posted $5.11 EPS. The company's revenue for the quarter was up .2% on a year-over-year basis. As a group, research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be paid a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.40%. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 10.09%.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the company's stock in a transaction dated Monday, April 28th. The shares were sold at an average price of $429.93, for a total transaction of $128,979.00. Following the transaction, the executive vice president directly owned 23,167 shares in the company, valued at approximately $9,960,188.31. This represents a 1.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.